Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 3Neoplasm Metastasis 2Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Muscle Invasive Bladder Urothelial Carcinoma 1Melanoma 1Lymphatic Metastasis 1Head and Neck Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 10 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 59Carboplatin 56Pemetrexed 47Cisplatin 39Paclitaxel 24Nivolumab 23Docetaxel 21durvalumab 20Gemcitabine 15130-nm albumin-bound paclitaxel 14osimertinib 13Cetuximab 12Specimen Handling 11Magnetic Resonance Spectroscopy 11atezolizumab 10amivantamab 8Taxes 8Radiotherapy 8Radiosurgery 7Ipilimumab 7lazertinib 6alectinib 6Ramucirumab 6Observation 6Bevacizumab 6cemiplimab 5Leucovorin 5Fluorouracil 5Etoposide 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × avelumab × 30 days × Clear all
NCT05267626 2026-05-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Aulos Bioscience, Inc.

Phase 1/2 Recruiting
159 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡